Ahmed A. Arif

机构：University of North Carolina at Charlotte · ORCID：0000-0002-0237-9937

发表论文 129 篇 · 总被引 5319 次 · h-index 32

代表论文

• Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial (2021 · The Lancet · 被引 669)
• Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US (2021 · JAMA Cardiology · 被引 248)
• Progression of COVID‐19 From Urban to Rural Areas in the United States: A Spatiotemporal Analysis of Prevalence Rates (2020 · The Journal of Rural Health · 被引 192)
• Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease (2021 · Stroke · 被引 125)
• Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial (2021 · European Heart Journal · 被引 122)
• A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function (2021 · Kidney International · 被引 95)